Stockreport

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer [Yahoo! Finance]

FibroGen, Inc  (FGEN) 
Last fibrogen, inc earnings: 3/2 04:01 pm Check Earnings Report
PDF cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as a companion PET im [Read more]